Pacific blue anti cd45 30 f11

Manufactured by BioLegend

Pacific blue (PB)-anti-CD45 (30-F11) is a fluorochrome-conjugated antibody that specifically binds to the CD45 antigen expressed on the surface of leukocytes. This product is intended for use in flow cytometry applications.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd16 cd32 antibody 2.4g2, by BD (2 mentions) Anti cd11b percp cy5.5 clone m1 70, by BioLegend (1 mentions) Anti ly6g pe clone 1a8, by BioLegend (1 mentions) Anti f4 80 pe clone bm8, by BioLegend (1 mentions) Facsaria 2, by BD (1 mentions) Alexa fluor 488 goat anti rabbit igg, by Thermo Fisher Scientific (1 mentions) Mec13, by BioLegend (1 mentions)

4 protocols using pacific blue anti cd45 30 f11

Multicolor Flow Cytometry Immune Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following fluorochrome-conjugated monoclonal antibodies (mAbs) were purchased from BioLegend (San Diego, CA): Pacific blue (PB)-anti-CD45 (30-F11), fluorescein isothiocyanate (FITC)-anti-F4/80 (BM8), phycoerythrin (PE)-anti-NK1.1 (PK136), PE-Cy7-anti-CD3 (145-2C11), PE-Cy7-anti-CD11c (N418), allophycocyanin (APC)-CD206 (C068C2), APC-Cy7-anti-CD11b (M1/70), APC-Cy7-anti-CD25 (PC61), Alexa Fluor (AF)-700-anti-CD8 (53-6.7), AF-700-anti-Ly6G/Ly6C (Gr-1, RB6-8C5); from BD Biosciences (San Jose, CA): FITC-anti-CD4 (GK1.5), PE-anti-CD86 (GL1); and from eBioscience (San Diego, CA): PE-anti-Foxp3 (FJK-16s), PE-Cy5-anti-MHCII (M5/114.15.2). Isotype-matched mouse, rat and hamster IgG mAbs were used as negative staining controls. In order to block FcγIII/II receptor-mediated unspecific binding, the anti-CD16/CD32 antibody (2.4G2) from BD Biosciences was used.

Kheirolomoom A., Ingham E.S., Mahakian L.M., Tam S.M., Silvestrini M.T., Tumbale S.K., Foiret J., Hubbard N.E., Borowsky A.D., Murphy W.J, & Ferrara K.W. (2015). CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery. Journal of controlled release : official journal of the Controlled Release Society, 220(0 0), 253-264.

+ Open protocol

+ Expand

Multicolor Flow Cytometry Immunophenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following fluorochrome-conjugated monoclonal antibodies (mAbs) were purchased from BioLegend (San Diego, CA): Pacific blue (PB)-anti-CD45 (30-F11), fluorescein isothiocyanate (FITC)-anti-F4/80 (BM8), phycoerythrin (PE)-anti-NK1.1 (PK136), PE-Cy7-anti-CD3 (145–2C11), PE-Cy7-anti-CD11c (N418), allophycocyanin (APC)-CD206 (C068C2), APC-Cy7-anti-CD11b (M1/70), APC-Cy7-anti-CD25 (PC61), Alexa Fluor (AF)-700-anti-CD8 (53–6.7), AF-700-anti-Ly6G/Ly6C (Gr-1, RB6–8C5); from BD Biosciences (San Jose, CA): FITC-anti-CD4 (GK1.5), PE-anti-CD86 (GL1); and from eBioscience (San Diego, CA): PE-Cy5-anti-MHCII (M5/114.15.2), PE-anti-H-2K^b-SIINFEKL (25-D1.16). Isotype-matched mouse, rat and hamster IgG mAbs were used as negative staining controls. To block FcγIII/II receptor-mediated unspecific binding, the anti-CD16/CD32 antibody (2.4G2) from BD Biosciences was used.

Kheirolomoom A., Silvestrini M.T., Ingham E.S., Mahakian L.M., Tam S.M., Tumbale S.K., Foiret J., Hubbard N.E., Borowsky A.D, & Ferrara K.W. (2019). Combining activatable nanodelivery with immunotherapy in a murine breast cancer model. Journal of controlled release : official journal of the Controlled Release Society, 303, 42-54.

+ Open protocol

+ Expand

Splenic Monocyte Isolation and Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Anti–F4/80-PE (clone BM8; BioLegend, San Diego, CA), anti–CD11c-PE (clone N418; BioLegend), anti–Ly6G-PE (clone 1A8; BioLegend), anti–CD11b-PerCP/Cy5.5 (clone M1/70; BioLegend), anti–CD45-Pacific Blue (30-F11; BioLegend), Fc-blocking purified anti-CD16/32 antibody (clone 93; BioLegend), and LIVE/DEAD fixable aqua dead cell stains (Invitrogen) were used for the flow cytometry analyses. Splenic monocytes were identified as CD45⁺ (F4/80/CD11c/Ly-6G)^low CD11b^high. The monocytes were sorted on a BD FACSAriaII (BD Biosciences, Franklin Lakes, NJ) and then collected for further studies including collagen uptake and Western blot analysis.

Lee T.H., McKleroy W., Khalifeh-Soltani A., Sakuma S., Lazarev S., Riento K., Nishimura S.L., Nichols B.J, & Atabai K. (2014). Functional genomic screen identifies novel mediators of collagen uptake. Molecular Biology of the Cell, 25(5), 583-593.

+ Open protocol

+ Expand

Whole-mount Sternum Immunofluorescence

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Whole-mount sternum immunofluorescence was performed as previously described (Asada et al., 2017 (link)). Mice were injected with Alexa Fluor 647-anti-CD144 (VE-Cadherin) (BV13, BioLegend, 5 μg per mouse) and Alexa Fluor 647-anti-CD31 (MEC13.3, BioLegend,cat, 5 μg per mouse) via the retro-orbital plexux 10 minutes before euthanasia. Sternal BM was exposed and fixed with 4% PFA for 20 min. Bone fragments were then washed in PBS and blocked/permeabilized in PBS containing 20% normal goat serum and 0.5% Triton X-100. Sternal bones were incubated with primary antibodies overnight. Primary antibodies used were anti-CD44-biotin (IM7, BioLegend,) and anti-CD45 pacific blue (30-F11, BioLegend). After washing in PBS, tissues were incubated with secondary antibodies for 2 hours. Secondary antibodies used were Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes, A-11034).

Boulais P.E., Mizoguchi T., Zimmerman S., Nakahara F., Vivié J., Mar J.C., van Oudenaarden A, & Frenette P.S. (2018). The majority of CD45− CD31− Ter119− bone marrow cell fraction is of hematopoietic origin and contains erythroid and lymphoid progenitors. Immunity, 49(4), 627-639.e6.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!